{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:22:59Z","timestamp":1773296579834,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T00:00:00Z","timestamp":1326672000000},"content-version":"vor","delay-in-days":3271,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2003,2]]},"abstract":"<jats:p>Inhaled anticholinergic drugs are considered one of the principal bronchodilator treatments for chronic obstructive pulmonary disease (COPD). Ipratropium bromide is an anticholinergic drug frequently administered for the treatment of COPD. Unfortunately, ipratropium has a short duration of action, requiring administration every 6 hours; this regimen affects adherence to drug therapy. Tiotropium bromide is structurally similar to ipratropium and is under development in the United States. The duration of action of tiotropium is approximately 24 hours, allowing for once\u2010daily dosing. Other than xerostomia being more common with tiotropium than with ipratropium, the safety profiles of these drugs were similar in studied populations. On the basis of its improvements in trough spirometric measurements and improved pharmacokinetic profile compared with that of ipratropium, tiotropium is likely to become the first\u2010line anticholinergic agent in the treatment of patients with COPD.<\/jats:p>","DOI":"10.1592\/phco.23.2.183.32082","type":"journal-article","created":{"date-parts":[[2004,5,11]],"date-time":"2004-05-11T07:16:40Z","timestamp":1084259800000},"page":"183-189","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Tiotropium: An Inhaled, Long\u2010Acting Anticholinergic Drug for Chronic Obstructive Pulmonary Disease"],"prefix":"10.1002","volume":"23","author":[{"given":"Chad A.","family":"Panning","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"DeBisschop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,16]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-7-200104030-00015"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200007273430407"},{"key":"e_1_2_1_4_2","unstructured":"PauwelsR. AnthonisenN. BaileyWC et al.Executive summary of global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease. National Heart Lung and Blood Institute\u2010World Health Organization (NHLBI\u2010WHO) workshop report 2001. Available fromhttp:www.goldcopd.comdocs.html. Accessed September 9 2002."},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(95)00020-7"},{"key":"e_1_2_1_6_2","first-page":"411","article-title":"Potential usefulness of inhibiting neural mechanisms in asthma","volume":"55","author":"Joos GF.","year":"2000","journal-title":"Monaldi Arch Chest Dis"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.supplement_1.17"},{"key":"e_1_2_1_8_2","first-page":"84","volume-title":"Goodman and Gilman's the pharmacological basis of therapeutics","author":"Lefkowitz RJ","year":"1990"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0026-895X(25)10204-6","article-title":"Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping","volume":"45","author":"Haddad EB","year":"1994","journal-title":"Mol Pharmacol"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(98)00588-8"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.154.4.8887578"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(93)90312-Q"},{"key":"e_1_2_1_13_2","first-page":"826","article-title":"The fate of inhaled drugs: the pharmacokinetics and pharmacodynamics of drugs administered by aerosol","volume":"45","author":"Witek TJ.","year":"2000","journal-title":"Respir Care"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.117.2_suppl.63S"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.150.6.7952627"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1183\/09031936.95.08091506","article-title":"Tiotropium bromide, a new long\u2010acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease","volume":"8","author":"Maesen FPV","year":"1995","journal-title":"Eur Respir J"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.4.9903044"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.118.5.1294"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00269802"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/145.6.1321"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.55.4.289"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00238702"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.122.1.47"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.117.2_suppl.67S"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.23.2.183.32082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:55:40Z","timestamp":1761065740000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.23.2.183.32082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,2]]}},"alternative-id":["10.1592\/phco.23.2.183.32082"],"URL":"https:\/\/doi.org\/10.1592\/phco.23.2.183.32082","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,2]]},"assertion":[{"value":"2012-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}